Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31312913 | 0.89 | LRRK2 (0.37) | FFAR4LRRK2PDE10A | |
| SCHEMBL26003250 | 0.89 | LRRK2 (0.37) | FFAR4LRRK2PDE10A | |
| SCHEMBL24207600 | 0.88 | FFAR4 (0.45) | FFAR4 | |
| SCHEMBL29021196 | 0.86 | ALDH1A1 (0.41) | — | |
| SCHEMBL29681555 | 0.85 | MAPT (0.38) | CHRM4LRRK2PDE10A | |
| SCHEMBL23983456 | 0.85 | MAPT (0.38) | CHRM4LRRK2PDE10A | |
| SCHEMBL30511792 | 0.85 | MYC (0.38) | LRRK2 | |
| SCHEMBL24801556 | 0.85 | S1PR5 (0.37) | — | |
| SCHEMBL30643645 | 0.84 | HTR1A (0.38) | CHRM4LRRK2 | |
| SCHEMBL25031311 | 0.84 | FFAR4 (0.48) | CHRM4FFAR4ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| EP-4291193-A1 | EGFR DEGRADERS AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2023-12-20 | — | — | EP | disclosed |
| CN-116847848-A | EGFR degrading agents and methods of use | 百济神州有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116745280-A | Bifunctional compounds for degrading EGFR and related methods of use | 百济神州有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022171123-A1 | EGFR DEGRADERS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022068849-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068849-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CHRM4 4779/4885CHRM2 4766/4885FFAR4 4207/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | CHRM4 4803/4885CHRM2 4773/4885FFAR4 4485/4885 |
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | EGFR, ERBB2, ERBB3 | CHRM4 4799/4885CHRM2 4787/4885FFAR4 3740/4885 |
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | CHRM4 4139/4885CHRM2 3830/4885FFAR4 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.